https://www.selleckchem.com/pr....oducts/Masitinib-(AB
Sinonasal malignancies rare and pathologically diverse and make up less then 1% of all malignancies. Due to their anatomical location, they can cause significant morbidity with involvement of surrounding critical structures. They often present at a late stage with insidious onset of symptoms. Treatment of sinonasal malignancies is challenging and they often require a multimodality approach with surgery, radiation, and chemotherapy. Outcomes are poor with 5-year overall survival around 32%, but this varies greatly depending on
Like
Comment
Share